Buchumschlag

Development and evaluation of a machine learning model to predict acute care for opioid use disorder among Medicaid enrollees engaged in a community‐based treatment program

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Lingshu Xue, Ruofei Yin, Evan S. Cole, Wei‐Hsuan Lo‐Ciganic, Walid F. Gellad, Julie Donohue, Lu Tang
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Addiction
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Refining cause of death attribution among opioid, opioid‐stimulant and stimulant acute toxicity deaths
von: Yi‐Shin Grace Chang, et al.
Veröffentlicht: (2025)

Questioning methadone split‐dosing for analgesia among hospitalized patients with opioid use disorder
von: Dale Terasaki, et al.
Veröffentlicht: (2024)

Navigating pregnancy and addiction recovery: Patient perspectives on perinatal care interventions for women with opioid use disorder in Kentucky, USA
von: Hilary L. Surratt, et al.
Veröffentlicht: (2026)

Increased cancer incidence and mortality among people with opioid use‐related disorders: A nation‐wide cohort study
von: Emil Kostovski, et al.
Veröffentlicht: (2024)

Evaluating the optimal duration of medication treatment for opioid use disorder
von: Corey J. Hayes, et al.
Veröffentlicht: (2026)

Associations among social determinants of health and opioid use disorder and overdose: An umbrella review
von: Lauren B. Loeffel, et al.
Veröffentlicht: (2026)

Primary care's most pressing needs to address opioid use disorder: A qualitative study
von: Elise A. Robertson, et al.
Veröffentlicht: (2026)

The Opioid Safety Toolkit: An interactive prescription opioid safety toolkit to increase opioid safety literacy and behaviours among people prescribed opioids for pain—a randomised controlled trial
von: Suzanne Nielsen, et al.
Veröffentlicht: (2026)

Systematic review of patient‐reported outcome measures for opioid use disorder recovery
von: Jarratt D. Pytell, et al.
Veröffentlicht: (2025)

An exploratory analysis of 5‐alpha reductase inhibitors and risk of opioid use disorder among male Medicare beneficiaries receiving prescription opioid medications
von: Abdelrahman G. Tawfik, et al.
Veröffentlicht: (2025)

Evaluating comparative effect of non‐pharmacological interventions adjunctive to opioid agonist therapy for opioid use disorder: A systematic review with network meta‐analysis
von: Bei Lv, et al.
Veröffentlicht: (2026)

Impact of study design decisions on identification of treatment initiators of medications for opioid use disorder
von: Payel J. Roy, et al.
Veröffentlicht: (2025)

Academic detailing is effective at altering clinician practice and patient outcomes for opioid use disorder
von: Jonathan Zhang, et al.
Veröffentlicht: (2026)

Trajectories of medication for opioid use disorder and their impact on HIV testing among people who inject drugs in India: A longitudinal assessment of clinic‐based data
von: Allison M. McFall, et al.
Veröffentlicht: (2024)

Commentary on D'Agata Mount et al.: Higher dose buprenorphine to improve retention in opioid use disorder treatment, prevent relapse, and optimize integrated care interventions
von: Paolo Mannelli
Veröffentlicht: (2024)

A descriptive analysis of rural‐urban overdose experiences among incarcerated women with opioid use disorder
von: Megan F. Dickson, et al.
Veröffentlicht: (2025)

Impact of enhanced practices on opioid overdose deaths: A community‐based modeling approach
von: Carolina Barbosa, et al.
Veröffentlicht: (2026)

Empirically contrasting urine drug screening‐based opioid use disorder treatment outcome definitions
von: Laura Brandt, et al.
Veröffentlicht: (2024)

Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all‐cause mortality among people with opioid use disorder: A retrospective population‐based target trial emulation study in British Columbia, Canada, 2010–2020
von: Ruyu Yan, et al.
Veröffentlicht: (2026)

A comparative study of treatment retention in opioid use disorder: Subcutaneous injectable versus sublingual buprenorphine
von: Charles Deng, et al.
Veröffentlicht: (2025)

The dopamine 3 receptor as a candidate biomarker and therapeutic for opioid use disorder
von: Matthew L. Banks, et al.
Veröffentlicht: (2024)

The impact of opioid, cannabis and cocaine use disorder on the risk of diabetic retinopathy in patients with type 2 diabetes mellitus
von: Ming‐Pei Yueh, et al.
Veröffentlicht: (2025)

Dose‐specific clinical outcomes in patients with opioid use disorder treated with 24–32 mg/day of buprenorphine
von: Julia D’Agata Mount, et al.
Veröffentlicht: (2024)

Pharmacological treatment strategies to manage precipitated withdrawal following the administration of buprenorphine in opioid use disorder: A systematic review
von: Emmert Roberts, et al.
Veröffentlicht: (2026)

Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type
von: Corey J. Hayes, et al.
Veröffentlicht: (2024)

Commentary on Schmidt et al.: Informed patient preference and prioritizing access to medications for opioid use disorder for pregnant individuals
von: Jake R. Morgan, et al.
Veröffentlicht: (2024)

Potential health impacts of comprehensive access to opioid use disorder treatment in United States correctional facilities: A synthetic analysis
von: Jake J. Smith, et al.
Veröffentlicht: (2025)

Associations of emotional experience with gaming duration and risk of gaming disorder among adolescent gamers: An ecological momentary assessment study
von: Camilla K. M. Lo, et al.
Veröffentlicht: (2025)

A pilot study of virtual reality for inpatients with opioid use disorder
von: Herbert J. Greenwald, et al.
Veröffentlicht: (2024)

Impact of baseline methamphetamine/amphetamine use on discontinuation of methadone and buprenorphine/naloxone among people with prescription‐type opioid use disorder in Canada
von: Jenna Langlois, et al.
Veröffentlicht: (2024)

Quantifying the impact of a large‐scale opioid agonist treatment program on suicide prevention in New South Wales, Australia: A data‐modeling study
von: Thomas James Santo, et al.
Veröffentlicht: (2025)

Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient‐ and prescriber‐level characteristics in Massachusetts, USA
von: Gary J. Young, et al.
Veröffentlicht: (2024)

Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018–2022
von: Rachael K. Ross, et al.
Veröffentlicht: (2024)

Multivariable machine learning prediction of risky alcohol use in contemporary youth
von: Lucinda Grummitt, et al.
Veröffentlicht: (2025)

Recovery support services as part of the continuum of care for alcohol or drug use disorders
von: Ed Day, et al.
Veröffentlicht: (2025)

Case Series: Magnitude and duration of fentanyl and xylazine detection in the urine of persons with opioid use disorder
von: Helen E. Bird, et al.
Veröffentlicht: (2025)

Updated OUD PIP: Take this free, updated PIP activity on treating opioid use disorder
Veröffentlicht: (2025)

Exploring clinical profile and treatment outcome differences based on baseline smoking and alcohol co‐use status among individuals initiating medication for opioid use disorder treatment
von: Gabriela León, et al.
Veröffentlicht: (2025)

Association between prescribed stimulant medications and overdose among individuals receiving opioid agonist therapy: A retrospective cohort study from British Columbia, Canada
von: Samantha Young, et al.
Veröffentlicht: (2025)

Identifying hazardous alcohol use in primary care using phosphatidylethanol: Timing of screening matters
von: Viktor Månsson, et al.
Veröffentlicht: (2025)